ReviewJournal of translational medicine2026
The cGAS-STING pathway and mitochondrial metabolism: from mechanistic insights to therapeutic potential in tumor.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- cGAS-STING signaling in aging and age-related diseases: therapeutic promise and precaution.Archives of pharmacal research · 2026Review
- New Functions of Mitochondrial Dysfunction in Gastric Cancer: From Molecular Processes to Potential Treatments.International journal of molecular sciences · 2026Review
- From energy metabolic homeostasis to immune remodeling: the role and therapeutic potential of STING signaling in the tumor microenvironment.Cell communication and signaling : CCS · 2026Review
- Mitochondrial-targeted actions of lycopene: evidence, mechanisms and future directions.Frontiers in pharmacology · 2026Review
- Microbial and metabolic signatures of humanized microbiome mice associate withFrontiers in immunology · 2026Article
- The mitochondrial DNA-cGAS-STING axis in colorectal cancer: a focused review of context-dependent roles and therapeutic opportunities.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway serves as the core cytoplasmic DNA-sensing signaling pathway and represents a pivotal node within the immune-metabolic regulatory network through its coordination with mitochondrial metabolism. MAIN BODY: Emerging evidence suggests that the cGAS-STING pathway plays a dual role in the tumor microenvironment (TME), promoting both anti-tumor immunity and tumor progression. These opposing effects are governed by the spatiotemporal dynamics of STING activation and the metabolic state of mitochondria. Recent studies have revealed that the clinical efficacy of STING agonists is constrained not only by the induction of chronic inflammatory responses but also by tumor metabolic heterogeneity. A comprehensive understanding of the mechanistic crosstalk between the cGAS-STING pathway and mitochondrial metabolism could provide a robust theoretical foundation for developing novel STING-targeted therapeutic strategies based on metabolic modulation.
conclusionThis review provides a systematic overview of the interactive regulatory mechanisms connecting the cGAS-STING pathway with mitochondrial metabolism and assesses the translational potential of targeting this immune-metabolic axis in the context of precision oncology. The insights discussed herein are intended to support the rational optimization and clinical application of STING agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.